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ABSTRACT
Carbon Storage Regulator A (CsrA) is an RNA bind-
ing protein that acts as a global regulator of di-
verse genes. Using a combination of genetics and
biochemistry we show that CsrA binds directly to
the 5′ end of the transcript encoding AcrAB. Dele-
tion of csrA or mutagenesis of the CsrA binding
sites reduced production of both AcrA and AcrB.
Nucleotide substitutions at the 5′ UTR of acrA mRNA
that could potentially weaken the inhibitory RNA sec-
ondary structure, allow for more efficient translation
of the AcrAB proteins. Given the role of AcrAB-TolC
in multi-drug efflux we suggest that CsrA is a poten-
tial drug target.
INTRODUCTION
Efflux pumps that belong to the resistance-nodulation di-
vision (RND) family, found in Gram-negative bacteria,
confer intrinsic and acquired multi-drug resistance (MDR)
in clinically relevant infections (1). Of the RND efflux
pumps, the tripartite AcrAB–TolC complex is best charac-
terized. Regulation of AcrAB expression is best understood
at the level of transcription initiation in Escherichia coli and
Salmonella enterica serovar Typhimurium. Hence, the local
regulator AcrR, and global regulator RamA, repress and
activate acrAB transcription respectively (2). Other AraC-
type transcription factors, closely related to RamA, can in-
fluence levels of AcrAB–TolC (3). Hence, MarA, SoxS and
Rob recognize the same DNA target as RamA and have
overlapping regulatory effects (Figure 1). It has also been
shown that expression of ramA is increased by mutational
inactivation of acrAB or when efflux is inhibited (4). It is
unknown if AcrAB–TolC expression is also controlled post-
transcriptionally.
Carbon storage regulator A (CsrA) is an extensively stud-
ied RNA binding protein homologous to the Pseudomonas
fluorescens repressor of secondary metabolites A (RsmA)
protein (5). Initially identified in E. coli K-12, CsrA is a
61-amino acid, dimeric RNA-binding protein that targets
sites in RNAmolecules (15,17–19). Studies have shown that
the primary consensus motif A(N)GGA is required for high
affinity binding of CsrA to target mRNA (6–9). CsrA sites
that deviate from the consensus are termed secondary and
bind CsrA with lower affinity (10). Hence, CsrA can modu-
late translation and transcript stability by controlling access
to the ribosome or RNA cleavage factors such as RNase E
(11–14).
In our study, we set out to identify factors involved in
regulation of ramA. To do this we used a ramA promoter-
GFP reporter plasmid and a transposon library of S. Ty-
phimurium SL1344. Using fluorescence-activated cell sort-
ing (FACS), bacteria with increased fluorescence were iso-
lated and genome sequencing identified genes conferring in-
creased ramA expression. Surprisingly, inactivation of csrA,
not previously implicated in control of ramA, increased
ramA expression. We determined that induction of ramA
in the csrAmutant was indirect and required CsrA binding
to the acrAB transcript. This enhances AcrAB expression
and so stabilizes the acrABmRNA. To our knowledge, this
study provides the first evidence for regulation ofmulti-drug
efflux and resistance by CsrA.
MATERIALS AND METHODS
Bacterial strains and plasmids
The strains and plasmids used in this study are shown in
Supplementary Table S1. Salmonella enterica serovar Ty-
phimurium strain SL1344 was used throughout unless in-
dicated otherwise. Mutants of SL1344, lacking functional
acrA, acrB, ramA, ramR or csrA genes, were constructed
using the method of Datsenko and Wanner (15). Comple-
mentation of the csrA mutant was done using a low copy
number vector pWSK30. The GFP transcriptional fusions
were made using the method described by Lawler et al.
(4). Hence, DNA fragments carrying the ramA oracrAB
promoter region, flanked by BamHI and XbaI restriction
sites, were cloned into the GFP reporter pMW82. Bacteria
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Figure 1. Transcriptional regulation of acrAB expression in Escherichia coli and Salmonella enterica. In both E. coli and S. enterica the acrAB regulon (•)
can be activated by the transcriptional activators, MarA (•), SoxS (•) and Rob (•). In S. enterica ramRA (•) is the master regulator of the acrAB regulon.
MarA, SoxS, Rob and RamA activate the acrAB regulon by directly binding to a degenerate nucleotide sequence upstream of the acrAB locus known as
the mar/sox/rambox. In E. coli and S. enterica acrR is the local repressor of acrAB, in S. enterica ramR acts as the local repressor of ramA.
were routinely cultured in Luria–Bertani broth (LB). Sigma
Aldrich supplied all chemicals and antibiotics, unless other-
wise stated.
Fluorescence-activated cell sorting (FACS) methodology
The S. Typhimurium SL1344 TraDIS library, containing
1 022 000 mutants, was constructed and kindly provided
by Gemma Langridge (The Wellcome Trust Sanger Insti-
tute). Transformation of the SL1344 TraDIS library with
the ramAGFP reporter plasmid (pMW82pramA) was done
using electroporation. Bacteria that expressed greater lev-
els of GFP compared to the negative controls (see below)
were identified using a BD FACSAria2 (BD Biosciences).
Cells were excited using a 488 nm wavelength laser; forward
scatter (FSC), side scatter (SSC) and green fluorescence
(via a 502 LP mirror and 530/30 BP filter) were measured.
Bacteria were gated from noise using a FSC versus SSC
plot. Positive and negative controls were pMW82pramA in
SL1344 ramR::aph (this over-expresses ramA and will give
a high GFP reading) and SL1344 ramA::aph (gives a ‘base-
line’ GFP level and prevents any auto-induction by RamA).
Cells expressing high levels of GFP compared to the neg-
ative control were sorted and collected. These sorted cells
were grown overnight aerobically at 37◦C on LB agar con-
taining ampicillin (50 g/ml). To confirm greater GFP ex-
pression random colonies were taken and fluorescence as-
says done using a FluoSTAR OPTIMA (BMG Labtech)
plate reader as described previously (16). DNA sequencing
with transposon specific primers determined sites of trans-
poson insertion.
Determination of gene expression
The effect of loss of csrA on the expression of genes en-
coding other XylS-AraC transcriptional activators, ramA,
marA, soxS, rob and of the efflux pump components acrA
and acrB were measured with real-time quantitative RT-
PCR as described by Blair et al. (17).
Western blotting
Cell pellets were re-suspended in 50 mM Tris/HCl (pH 8.0)
and sonicated (4 30 s pulses with a 30 s pause between each
pulse) on ice using an MSE Soniprep 150 (Sanyo, UK).
A Bradford assay was done to quantify protein concen-
tration and 10 g of protein was electrophoresed on 4–
12% NuPAGE® Bis-Tris mini gels in NuPAGE® MES
SDS running buffer (Life Technologies, UK). Proteins were
transferred to a PVDF membrane (Amersham) by elec-
trophoresis for 3 h at 4◦C and the membrane blocked with
5% non-fat milk solution. After overnight incubation with
antibodies for AcrA, AcrB or FLAG, membranes were
washed overnight and incubated with an HRP-linked anti-
rabbit secondary antibody (GEHealthcare). The Enhanced
chemiluminescence (ECL) western blotting detection sys-
tem (GE Healthcare) was used to identify bound antibody.
Purification of CsrA-HisX6 protein
Plasmid pCSB12 containing csrA cloned into the NdeI and
BamHI sites of pET21a+ (Inovagen) was kindly donated to
us by Tony Romeo (University of Florida, USA). In order
to prevent contamination by the RNA binding protein Hfq
in the purification procedure, pCSB12was transformed into
BL21 (DE3) pLysE (Invitrogen) cells in which the hfq gene
had been deleted. The BL21 (DE3) pLysE/hfq::aph strain
containing pCSB12 was cultured at 37◦C in LB broth with
vigorous shaking until an OD600 nm of 0.6 was attained. Ex-
pression of CsrA-HisX6 was induced for 5 h by adding Iso-
propyl -D-1- thiogalactopyranosid (IPTG) to a final con-
centration of 1 mM. Cells were harvested by centrifuga-
tion (4000 × g for 20 min at 4◦C) and the cell pellet was
frozen at −20◦C until further use. Purification of CsrA-
HisX6 was done using a QIAexpress® Ni-NTA spin kit
(Qiagen). Briefly, the cell pellet was thawed on ice for 15
min and re-suspended in 10 ml native lysis buffer. After in-
cubation on ice for a further 30 min cell debris was removed
by centrifugation (14000 × g for 30 min at 4◦C). The cell
lysate was then applied to a Fast Start Column contain-
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ing re-suspended resin. The flow through fraction was col-
lected and stored at −20◦C. The column was washed twice
with 4 ml of native Wash Buffer with each wash fraction
being collected and stored at −20◦C. Bound CsrA-HisX6
tagged protein was eluted with two 1 ml aliquots of Na-
tive Elution Buffer. Each elution fraction was collected sep-
arately and stored at −20◦C. All fractions were analyzed by
sodium dodecyl sulphate-polyacrylamide gel electrophore-
sis and Coomassie Blue staining as well as western blotting
with anti-His tag antibody (Thermo Fisher Scientific). The
second elution fraction was also analyzed by Fourier trans-
form ion cyclotron resonance (FT-ICR) mass spectrometry
(Supplementary Table S3) and was used for all the subse-
quent in vitro experiments. The CsrA-HisX6 concentration
was estimated using the Bradford protein assay (18).
RNA electrophoretic mobility shift assays
Known binding sites for CsrA were sought based upon
data described by Kulkarni et al., (10). RNA transcripts
corresponding to the promoter regions of acrAB (includ-
ing wild-type and those harboring site directed mutations),
and ramA were synthesized in vitro using the AmpliS-
cribe™ T7-Flash™ Transcription Kit (Cambio Ltd, UK)
and purified by ammonium acetate precipitation. Concen-
trations of transcripts were determined with the Qubit™
fluorometric quantitation system (Life Technologies, UK).
The electrophoretic mobility shift assay was done using an
electrophoretic mobility shift assay (EMSA) kit (E33075;
Thermo Fisher, UK) according to the manufacturer’s in-
structions. Briefly, 0.5 nM target RNA was incubated with
CsrA-HisX6 protein for 20 min at room temperature in a 15
l reaction mixture containing 1× binding buffer (750 mM
KCl, 0.5 mM dithiothreitol, 0.5 mM ethylenediaminete-
traacetic acid (EDTA), 50 mM Tris–HCl, pH 7.4). Fol-
lowing addition of EMSA gel-loading solution, mixtures
were separated by electrophoresis on a non-denaturing 8%
(wt/vol) polyacrylamide gel in 0.5 × TBE buffer (22 mM
Tris-HCl, 22 mM boric acid, 0.5 mM EDTA, pH 8.0). Gels
were stained with 1 × SYBR Green EMSA nucleic acid
stain. DNAwas then visualized using a G:BOX F3 gel doc-
umentation system (Syngene, UK).
Construction of the AcrA::GFP translational reporter fusion
A 1525-bp DNA fragment containing acrA and its pro-
moter region was amplified from SL1344 genomic DNA
using PCRprimers 5′-GGGGGATCCGCTCCCAGATCT
CACTGAAT-3′ and 5′-GGGGTACCAGACCTGGGCT
GAGCAGGTTG-3′. This PCR product was cloned in
BamHI/KpnI digested pDOC-G (19), to form the transla-
tional fusion plasmid pAcrA-TF.
Site-directed mutagenesis of the CsrA binding sites in the
acrAB leader region
For our initial CsrA binding experiments the GGA mo-
tifs in the CsrA binding sites in the leader sequence
of acrAB were mutated to GTA using the QuikChange
Site Directed Mutagenesis kit (Stratagene). The G to T
substitutions were introduced into the acrAB leader se-
quence on pMW82pacrAB and pCR®II-pacrAB result-
ing in plasmids, pMW82pacrAB (CsrA BS-SDM) and
pCR®II- pacrAB (CsrA BS-SDM). To investigate the role
of RNase E degradation, nucleotides in the acrAB leader se-
quence, which contain putative RNase E cleavage sites, were
deleted using the QuikChange Site Directed Mutagenesis
kit (Stratagene). The resulting plasmid was pMW82pacrAB
(RNase E- DEL). To assess positive regulation of AcrAB
expression by CsrA nucleotide substitutions were made in
the CsrA binding regions. Two sets of nucleotide substi-
tutions were made; 5′-TAAGGAC-3′ to 5′-GCTATGT-3′
and 5′-TCGGAC-3′ to 5′-GTCTGA-3′. Nucleotide substi-
tutions were made using the QuikChange Lightning Multi
Site-Directed Mutagenesis Kit (Stratagene).
In vitro coupled transcription-translation assay
Plasmid pT7-acrA-GFP contains a T7 promoter driving
transcription of an acrA-GFP translational fusion. Plas-
mid pT7-acrA-GFPMut CsrA BS is identical to pT7-acrA-
GFP except that it contains TAAGGAC to GCTATGT
and TCGGAC to GTCTGA mutations in the two pre-
dicted CsrA binding sites in the leader sequence of acrA.
Both plasmids were purified using the Plasmid Midiprep
Kit (Qiagen) followed by phenol/chloroform extraction
and ethanol precipitation. These two plasmids were used
as the templates for coupled transcription-translation reac-
tions using the PURExpress® In Vitro Protein Synthesis
Kit (New England BioLabs). Reaction mixtures containing
50 ng plasmidDNA template in the absence and presence of
320 nM of purified His-tagged CsrA were incubated for 2 h
at 37◦C. Fluorescence was measured at excitation and emis-
sion wavelengths of 492 and 520 nm, respectively, using a
FLUOstar Optima (BMG labtech).
RNAsecondary structure prediction of wild-type andmutated
acrAB transcripts
The RNA secondary structures of wild-type and mutated
acrAB RNA transcripts were predicted with ViennaRNA
Package 2.0 (20).
mRNA stability assay
Strains were cultured at 37◦C in LB medium to OD600 nm
of 0.8 and treated with rifampicin (200 g/ml) to inhibit
transcription (21). After 0, 1, 2, 3, 4 and 5 min of ri-
fampicin treatment cells were harvested by centrifugation
(4000 × g) and RNA extracted using the Wizard SV RNA
kit (Promega, UK). The amount of acrB, ramA and gfp
mRNA in each sample was determined by real-time quan-
titative RT-PCR as described by Blair et al., (17). The per-
centage of RNA remaining at each time-course was de-
termined by calculating the difference in cycle threshold
(CT) compared to the 0-min time point after taking into
account 16S rRNA levels, as per manufacturer’s instruc-
tions (Bio-Rad, UK).
Induction assays
To observe induction of AcrAB fromour translational GFP
reporter construct in SL1344 and SL1344 csrA::aph we
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measured fluorescence following the addition of 2 mM in-
dole, using the method described by Lawler et al., (4). Two
biological and three technical replicates of each culture were
used in each assay. Simultaneous measurement of fluores-
cence at excitation and emission wavelengths of 492 and 520
nm, respectively, and absorbance at a wavelength of 600nm
was carried out in a FLUOstar Optima (BMG labtech) at
an incubation temperature of 37◦C.
Growth kinetics and determination of susceptibility to antimi-
crobials
Growth rates in LB broth or minimal medium (Teknova,
USA) were determined over 24 h at 37◦C using a FLUOstar
OPTIMA (BMG Labtech, UK) plate reader as previously
described (22). The minimum inhibitory concentration of
each antimicrobial tested was determined by the standard-
ized agar doubling-dilution method as described previously
by the BSAC (http://www.bsac.org.uk) (23).
Biofilm formation and curli synthesis
Biofilm formation and curli synthesis by SL1344, SL1344
csrA::aph and SL1344 csrA::aph pWSK30csrA was deter-
mined as described previously by Baugh et al., (24).
Adhesion and invasion assays
The ability of strains to adhere to, and invade, INT 407 (hu-
man embryonic intestine cells) was measured as previously
described (25). Each assay was repeated aminimumof three
times, with each experiment including four technical repli-
cates per bacterial strain.
Statistical analysis
Data obtained in this study are from at least three inde-
pendent experiments and are shown as means ± standard
deviation. Statistical significance was determined with the
Students t-test where P < 0.05 was regarded as statistically
significant.
RESULTS
A screening assay with a GFP reporter identified CsrA as a
potential regulator of ramA
A S. Typhimurium SL1344 transposon library was used to
identify factors important for ramA expression. Briefly, the
library was transformed with plasmid pMW82pramA en-
coding an unstable GFP derivative under the control of
the ramA promoter. Cells with increased GFP fluorescence,
compared to a negative control, were isolated using FACS
(Figure 2) and cultured on LB agar. Twenty colonies were
selected and for the eight isolates showing the greatest fluo-
rescence we identified csrA (n = 2), flgL (n = 1), ccmA (n =
2), ccmB (n = 1) and alaS (n = 2) as the site of transposon
insertion. Since CsrA has a known role in controlling gene
expression we focused on this factor.
Figure 2. Output fromFACS following transformation of pMW82-pramA
into Salmonella enterica serovar Typhimurium transposon library post 2 h
recovery incubation at 37◦C.Cell populations expressing greaterGFP than
the negative control were gated into populations P4, P5, P6 and P7 before
sorting.
csrA inactivation affects growth, biofilm formation and viru-
lence but does not affect susceptibility to antimicrobials
A SL1344 csrA::aph mutant was constructed and to check
that it behaved as expected we investigated the proper-
ties of this mutant. Consistent with previous observations
(26–28) the SL1344 csrA::aph mutant was defective for
both planktonic growth and biofilm formation. Further-
more, these phenotypes were reversed upon complementa-
tion with wild-type csrA (Supplementary Table S2). Inacti-
vation of csrA also attenuated the virulence of Salmonella
(Supplementary Figure S2) but no difference in susceptibil-
ity to tested antimicrobials was observed (Supplementary
Table S2).
Absence of csrA/CsrA increases expression of transcriptional
activators but not efflux pump components
Transcription of ramA in SL1344 csrA::aph increased by
4.2 ± 1.6-fold (Table 1). Since RamA activates acrAB ex-
pression, we reasoned that expression of these genes should
also increase in cells lacking csrA. Hence, the plasmid
pMW82pacrAB was used to transform SL1344 csrA::aph
or the parent strain. Surprisingly, loss of csrA caused no in-
crease in acrAB transcription (1.16 ± 0.88-fold) (Table 1).
These observations were confirmed by real-time quantita-
tive RT-PCR (Table 1) whilst western blotting indicated re-
duced translation of AcrA and AcrB (Figure 3A and B). In-
terestingly, expression of marA and soxS increased in cells
lacking csrA (Table 1).
CsrA binds to the leader region of acrAB but not to ramA
The lack of acrAB induction led us to question why ramA
expression increased in the SL1344 csrA::aph mutant. In
previous work, we showed that increased expression of
ramA occurs when acrAB is inactivated (4,29). Therefore,
we hypothesized that CsrA may influence ramA expression
indirectly by targeting expression of acrAB. This model
would explain the negative correlation between ramA and
Nucleic Acids Research, 2017 5
Table 1. Gene and protein expression of efflux pump components and regulators in SL1344 csrA::aph and MDR S. Typhimurium and their respective
csrA mutants
Gene/protein SL1344 csrA::aph
SL1344
ramR::aph
SL1344
ramR/csrA::aph
SL1344 MDR
mutant
SL1344 MDR
mutant/csrA::aph
Fold change in gene/protein expression compared to SL1344
GFP RT-PCR Protein RT-PCR RT-PCR RT-PCR RT-PCR
ramA/RamA 4.2 ± 1.6* 3.8 ± 1.8* 24.5* 3.8 ± 0.2* 4.9 ± 0.2* 3.1 ± 0.1* 4.1 ± 0.3*
acrAB 1.2 ± 0.9 ND ND ND ND ND ND
acrA/AcrA ND 1.02 ± 0.04 0.2* 2.7 ± 0.2* 2.8 ± 0.1* 2.5 ± 0.2* 2.2 ± 0.2*
acrB/AcrB ND 1.03 ± 0.03 0.2* 3.9 ± 0.2* 3.7 ± 0.3* 3.2 ± 0.2* 3.1 ± 0.3*
marA ND 3.1 ± 1.4* ND ND ND ND ND
soxS ND 4.1 ± 1.1* ND ND ND ND ND
csrA ND ND ND 1.1 ± 0.03 1.03 ± 0.03
GFP expression data were obtained from fluorescence assays performed with the ramA and acrAB GFP transcriptional fusions as described in the ‘Materials and Methods’
section. RT-PCR expression data was obtained by using a real-time quantitativemethod as described by Blair et al., (17). Protein expression data was obtained bywestern blotting
and fold change expression data relates to data described in Figure 3. Values were calculated from three biological replicates; ±standard deviation, *P< 0.05 by Student’s t-test,
Increased expression, bold font; decreased expression, italics. ND, not done.
acrAB expression in cells lacking CsrA. Furthermore, re-
duced efflux would be consistent with enhanced expression
of marA and soxS described above (Table 1). Consistent
with ourmodel, only a putative secondaryCsrAbinding site
could be identified in the ramA mRNA leader (Figure 4A)
and this was insufficient to bind CsrA in vitro (Figure 5A).
Conversely, analysis of the acrAB promoter sequence iden-
tified both primary (AAGGA) and secondary (TCGGA)
CsrA targets (Figure 4B) that bound CsrA tightly (Figure
5B). A non-linear least squares analysis of the data revealed
a Kd value of 46.27 ± 3.7 nM (Figure 5D). To establish
whether the putative CsrA binding sites were responsible for
the observed mobility shift the sites AAGGA and TCGGA
were mutagenized to AAGTA and TCGTA, respectively.
No mobility shift was observed with these control RNA
templates (Figure 5C). Furthermore, mutation of the CsrA
binding sites in the acrABmRNA leader reduced expression
of downstream-encoded GFP 3.2-fold.
CsrA positively regulates AcrAB protein levels by stabilizing
acrAB mRNA
CsrA primarily regulates gene expression by preventing
translation initiation (14). Our data suggest that CsrA is a
positive regulator of acrAB. As a first step toward under-
standing this positive regulation we considered the possi-
bility that CsrA might stabilize the acrAB mRNA. Hence
stability of the acrAB transcript was quantified in SL1344
or the csrA::aph derivative. Five minutes after the addition
of rifampicin, which inhibits transcription initiation, most
acrAB mRNA remained in SL1344 cells. Conversely, a 2-
fold reduction in acrABmRNAwas observed in the absence
of CsrA (Figure 6A). Mutation of the acrAB CsrA binding
sites on the translational fusion, pAcrA-TF-SDM, had a
similar but smaller effect on the stability of acrA-gfp tran-
script (Figure 6B).
CsrA promotes efficient translation of AcrAB
In order to further determine whether CsrA en-
hances acrAB translation we used the in vitro coupled
transcription-translation PURExpress system. Two plas-
mid constructs, one carrying an acrA-GFP translational
fusion with wildtype leader sequence and another carrying
an acrA-GFP translational fusion with mutated CsrA
binding sites were used in this analysis. Expression from
each construct was measured by determining fluorescence.
Addition of CsrA-His6X to the system caused a 1.32 ±
0.02-fold increase in expression of the acrA-GFP construct,
containing the wildtype leader sequence. In contrast,
expression of the acrA-GFP translational fusion with
mutated CsrA binding sites construct was not significantly
changed in the presence of CsrA-His6X compared to
expression observed in the absence of CsrA-His6X (Figure
7). We conclude that CsrA directly stabilizes the acrAB
mRNA and that bound CsrA enhances translation of
AcrAB. These data also suggest that the effect of CsrA on
acrBmRNA stability (Figure 6A and B) was a consequence
of RNA secondary structure. We reasoned that CsrA might
alter acrAB mRNA structure to enhance translation and
transcript stability. To understand the likelihood of this
scenario, we predicted secondary structure of the acrAB
mRNA leader sequence. The prediction suggests extensive
intramolecular base pairing that occludes both the ribo-
some binding site and the CsrA targets (Figure 8A–C).
Binding of CsrA is likely to disrupt this repressive RNA
structure. If this model is correct, it should be possible
to mutate the acrAB mRNA so that intramolecular base
pairing is reduced and the requirement for CsrA is relieved.
Fortuitously, the mutations described above, that ablate the
CsrA binding sites, are also expected to reduce intramolec-
ular base pairing. Hence, we predicted that disrupting the
CsrA target sequences in cells lacking CsrA should have
a positive effect on acrA-gfp expression. As predicted,
mutation of the CsrA binding sites caused increased GFP
expression in the SL1344 csrA::aph mutant (Figure 9).
These data also explain why the effect of mutating the CsrA
targets has a smaller effect than deleting the CsrA gene; the
mutations simultaneously ameliorate CsrA binding and
intramolecular base pairing.
Indole induces AcrAB to a greater degree in the presence of
CsrA
Previous work has shown that the acrAB locus in
Salmonella is induced by indole (4,30,31). This induction
is dependent on RamA and requires the binding of RamA
to a binding sequence (ram-box) located upstream of acrA
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A
B
C                                                                                                             
AcrB 114 kDa
Relave [AcrB] %
100                         0                       224.8 18.4
100                   0                     369.86                    22.3
100                    0                  3224.8                2450.4
SL1344       ∆acrA ramR::aph       csrA::aph
SL1344       ∆acrB ramR::aph       csrA::aph
SL1344       ∆ramA ramR::aph        csrA::aph
AcrA 42 kDa
Relave [AcrA] %
RamA3XFLAG 16 kDa
Relave [RamA3XFLAG] %
RNA polymerase β subunit 
150 kDa
Relave [RNA pol] %
RNA polymerase β subunit 
150 kDa
Relave [RNA pol] %
RNA polymerase β subunit 
150 kDa
Relave [RNA pol] %
100                        99.8                     99.3                      98.3
100                    100.3                  102.2   100.6
100                    101.2             102.8                 103.14
Figure 3. Effect of csrA inactivation on protein levels of AcrA, AcrB
and RamA3XFLAG. (A) Expression of AcrA in SL1344 (WT), acrA,
ramR::aph and csrA::aph mutants. (B) Expression of AcrB in SL1344
(WT), acrB, ramR::aph and csrA::aph mutants. (C) Expression of
RamA3XFLAG in SL1344 (WT), ramA, ramR::aph and csrA::aph mu-
tants. Internal control used in all the experiments was the  subunit of
RNA polymerase. The RNA polymerase western blot confirms that there
is an equal amount of protein in each well. Band intensity was determined
usingGeneSys, this informationwas used to assign a relative concentration
of AcrA, AcrB and RamA3XFLAG to each respective band, expressed as
a percentage of wild-type. For negative controls, the respective deleted gene
mutant i.e. acrA, acrB and ramA mutants, were used.
(31). To investigate the role CsrA we compared induction
of acrAB by indole in SL1344 and the csrA::aph derivative;
induction was reduced in the absence of CsrA (Figure 10).
Deletion of csrA in aMDRmutant confers amore susceptible
phenotype
As noted above deletion of csrA has little effect on an-
tibiotic sensitivity in wild-type Salmonella. However, since
over-expression of AcrAB is important for multidrug re-
sistance, we set out to determine if loss of csrA from mul-
tidrug resistant S. Typhimurium strains might have a more
Figure 4. DNA sequence of the ramA and acrAB promoter regions used
in this study. (A) DNA sequence of the Salmonella enterica serovar Ty-
phimurium (SL1344) 288 bp ramRA intergenic region. The ramA promoter
−10 and −35 elements, and transcription start site (TSS) are in bold type.
The ribosomal binding site is underlined and the putative CsrA binding
site is in bold and shaded gray. (B) DNA sequence of the S. Typhimurium
(SL1344) 141 bp acrAB promoter region. The acrAB promoter −10 and
−35 elements, and predicted TSS are in bold type. The ribosomal bind-
ing site is underlined and the putative CsrA binding sites are in bold and
shaded gray. The deleted sequence containing putative RNase E cleavage
sites is indicated with dotted lines.
prominent effect. Susceptibility to ciprofloxacin, nalidixic
acid, tetracycline and chloramphenicol in two MDR mu-
tants (SL1344ramR and SL1344MDR) lacking csrA was
increased by between 2- and 4-fold (Supplementary Table
S2). We also determined the impact of csrA deletion on
drug efflux. Our data showed that ethidium bromide efflux
in theMDRmutants lacking csrAwas slower than in the re-
spective parent strains (Supplementary Figure S3). Consis-
tent with our model for regulation of acrAB translation by
CsrAwe observed no difference in acrAB transcript levels in
MDR Salmonella mutants lacking csrA whilst ramA tran-
scription was enhanced (Table 1). However, levels of AcrB
in the S. Typhimurium MDR mutants were reduced in the
absence of CsrA (Figure 11).
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Figure 5. RNA electrophoretic mobility shift analysis to evaluate ramA
and acrAB RNA interactions with CsrA. (A) In vitro transcribed ramA
RNA (0.5 nM) was incubated with the various concentrations of CsrA in-
dicated at the bottom of each lane. The positions of bound and free RNA
are shown at the left of each panel. (B) In vitro transcribed acrABRNA (0.5
nM) was incubated with the various concentrations of CsrA indicated at
the bottom of each lane. The positions of bound and free RNA are shown
at the left of each panel. (C) Effect of mutating putative CsrA binding sites
on CsrA-acrABRNA interactions. RNA electrophoretic mobility shift as-
says were performed using mutant acrAB RNA (0.5 nM). The concentra-
tion of CsrA was indicated at the bottom of each lane. The positions of
bound and free RNA are shown. (D) Binding curve for the reaction shown
in B.
DISCUSSION
In this study, we show that CsrA binds to and stabilizes the
acrABmRNA. From our in silico data, we propose a mech-
anism whereby CsrA binding prevents formation of a re-
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Figure 6. Absence of CsrA and CsrA binding sites on acrB and acrA-gfp
mRNA stability. (A) Analysis of acrBmRNA stability in Salmonella enter-
ica serovarTyphimuriumwild-type and csrAmutant strain. (B) Analysis of
acrA-gfp mRNA stability in S. Typhimurium containing pAcrA-TF-WT
and pAcrA-TF-SDM translational GFP fusions.
Figure 7. Effect of CsrA on acrA-GFP translation. Coupled transcription-
translation reactions were performed with a PURExpress kit using pT7-
acrA-GFP and pT7-acrA-GFP Mut CsrA BS translational fusions in the
presence and absence of purified CsrA-His protein (320 nM). Fluorescence
was measured at excitation and emission wavelengths of 492 and 520 nm,
respectively using a FLUOstar Optima. Each experiment was performed
three times.
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Figure 8. Primary sequence and secondary RNA structures of WT and
mutant acrAB leader regions. Primary DNA sequence of wildtype 5′ UTR
of acrAB and mutated 5′ UTR of acrAB in which the nucleotides making
up the CsrA binding sites have been substituted (gray shaded box). Ribo-
some binding site (dashed rectangle box). (A) The RNA structures of the
acrAB upstream region in the two plasmids of pAcrA-GFP-WT (B) and
pAcrA-GFP-SDM (C) were predicted by RNAfold and their folding free
energies were −12.30 kcal/mol and −6.0 kcal/mol, respectively. (Substi-
tuted nucleotides in gray shaded box)
Figure 9. AcrA-GFP expression from the wildtype and mutated acrAB
leader region. GFP expression from the wildtype (pAcrA-GFP-WT) and
mutated (pAcrA-GFP-SDM) translational fusions in SL1344 and SL1344
csrA::aph. GFP levels were calculated from three biological replicates; er-
ror bars indicate the standard deviation.
pressive RNA structure that impedes binding of the ribo-
some. To date there are only a few examples of CsrA, or
its homologue RsmA, acting to increase gene expression.
For example, in E. coli CsrA positively regulates flhDC by
binding two sites in the flhDC mRNA leader that prevent
transcript cleavage by RNase E (21). At the E. coli moaA
locus, the moa mRNA leader sequence contains two CsrA-
binding sites and also constitutes a molybdenum cofactor-
sensing riboswitch. This mechanism is the first example of
a riboswitch aptamer that interacts with two regulatory fac-
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Figure 10. Induction of AcrB in SL1344 and SL1344 csrA::aph in the pres-
ence of 2 mM indole. GFP levels were calculated from three biological
replicates; error bars indicate the standard deviation.
tors, a ligand and an RNA binding protein. Two studies
have suggested a mechanism of activation whereby CsrA
blocks the formation of an inhibitory structure at the RNA
5′ end (32,33). Although implied, these studies did not di-
rectly show the effect CsrA or RsmA had on mRNA sta-
bility. Here, we have shown that CsrA plays an important
role in stabilizing acrB mRNA and thus promoting opti-
mal translation of AcrAB. Our data show that binding of
CsrA to the acrAB transcript alters RNA structure and we
propose that this makes the ribosome binding site more ac-
cessible in a similar manner to that described previously by
Ren et al. for the action of RsmA at thePseudomonas aerug-
inosa phenazine biosynthetic gene clusters, phz1 and phz2,
(33). Our data from indole induction experiments suggests
that CsrA is required for optimal AcrAB expression in re-
sponse to a stimulus.
This is the first example of CsrA regulating the ex-
pression of an RND type efflux pump in any bacterium.
Understanding the molecular basis of intrinsic and ac-
quired MDR via efflux pumps is essential if new drugs
are to be discovered that are not susceptible to this mech-
anism (http://www.pewtrusts.org/~/media/assets/2016/05/
ascientificroadmapforantibioticdiscovery.pdf). Identifying
factors that could be inhibited and so reduce efflux could
form the basis of a drug discovery program. We postulate
that CsrA is a potential new drug target.
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Figure 11. AcrB expression levels in SL1344, MDR mutants of SL1344 and respective csrA mutants. Expression of AcrB in SL1344 (WT), csrA::aph,
ΔacrB, ramR::aph, ΔramR/ csrA::aph, MDR mutant and MDR mutant/csrA::aph. Internal control used in the experiment was the  subunit of RNA
polymerase. The RNA polymerase Western blot confirms that there is an equal amount of protein in each well. Band intensity was determined using
GeneSys, this information was used to assign a relative concentration of AcrB to each band, expressed in percentage of wild-type. A acrB mutant was
used as a negative control.
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